Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network

被引:0
|
作者
Conover, Mitchell M. [1 ,2 ]
Albogami, Yasser [1 ,3 ]
Hardin, Jill [1 ,2 ]
Reich, Christian G. [1 ,4 ]
Ostropolets, Anna [1 ,2 ,5 ]
Ryan, Patrick B. [1 ,2 ,5 ]
Observational Hlth Data Sci and Informatics OHDSI Res Network
机构
[1] Observat Hlth Data Sci & Informat, New York, NY 10032 USA
[2] Johnson & Johnson, Observat Hlth Data Analyt, Titusville, NJ 08560 USA
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
[4] IQVIA, Real World Solut, Cambridge, MA USA
[5] Columbia Univ, Dept Biomed Informat, New York, NY USA
关键词
chronic lower respiratory disease; common data model; glucagon-like peptide 1 receptor agonists; pharmacoepidemiology; real world data; real world evidence; reliability; replicability; reproducibility; transparency; REPRODUCIBILITY; CALIBRATION; BALANCE;
D O I
10.1002/pds.70087
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionThe aim of this study is to use observational methods to evaluate reliability of evidence generated by a study of the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) on chronic lower respiratory disease (CLRD) outcomes among Type-2 diabetes mellitus (T2DM) patients.Research Design and MethodsWe independently reproduced a study comparing effects of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4-i) on CLRD outcomes among patients with T2DM and prior CLRD. We reproduced inputs and outputs using the original study data (national administrative claims) and evaluated the robustness of results in comparison to alternate design/analysis decisions. To evaluate generalizability, we applied an analysis protocol and conducted a meta-analysis across a research network that includes a diverse array of populations and data sources. We also produced additional analyses evaluating individual drugs within the GLP-1RA class and CLRD outcomes.ResultsWe confirmed alignment of study inputs and outputs and closely reproduced effect estimates and sensitivity analyses. Adjusted effect estimates were robust to empirical calibration. Network meta-analysis confirmed original findings but indicated weaker effects than originally published. Meta-analysis of drugs within the GLP-1RA class against DPP4-i provided evidence that effects vary within the GLP-1RA class, indicating stronger effects for exenatide and weaker effects of dulaglutide.ConclusionsThis study supports and establishes the reliability of the original study by (1) producing consistent findings in a range of alternate databases and populations, (2) demonstrating effects for multiple drugs within the GLP-1RA class, and (3) independently confirming the reproducibility of the original study and its findings. This reliability evaluation provides the beginnings of a broader framework for using standardized tools and distributed data networks to systematically interrogate the reliability of findings generated using observational data.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] COPD Exacerbations in Patients With Type 2 Diabetes on Glucagon-like Peptide-1 Receptor Agonists
    Foer, D.
    Strasser, Z. H.
    Cui, J.
    Cahill, K. N.
    Murphy, S. N.
    Karlson, E. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [12] Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
    Mosenzon, Ofri
    Schechter, Meir
    Leibowitz, Gil
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 347 - 360
  • [13] Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
    Tran, Kelvin Lingjet
    Park, Young In
    Pandya, Shalin
    Muliyil, Navin John
    Jensen, Brandon David
    Huynh, Kovin
    Nguyen, Quang T.
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (04): : 178 - 187
  • [14] Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?
    Ling, James
    Chow, Elaine
    MED, 2024, 5 (08): : 845 - 847
  • [15] Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
    Vikulova, O. K.
    Zuraeva, Z. T.
    Michaleva, O., V
    Nikankina, L., V
    Shamkhalova, M. Sh
    Shestakova, M., V
    Dedov, I. I.
    TERAPEVTICHESKII ARKHIV, 2018, 90 (06) : 59 - 64
  • [16] Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Suicide and Self-Harm among Patients with Type 2 Diabetes
    Shapiro, Samantha
    Azoulay, Laurent
    Yin, Hui
    Yu, Oriana Hoi Yun
    Rej, Soham
    Suissa, Samy
    DIABETES, 2024, 73
  • [17] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Ju-Ming Lu
    Advances in Therapy, 2019, 36 : 798 - 805
  • [18] Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management
    Lambert, Lynn
    SA PHARMACEUTICAL JOURNAL, 2013, 80 (03) : 24 - 26
  • [19] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Lu, Ju-Ming
    ADVANCES IN THERAPY, 2019, 36 (04) : 798 - 805
  • [20] Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management
    Lambert, Lynn
    SOUTH AFRICAN FAMILY PRACTICE, 2013, 55 (06) : 511 - 514